AGL 38.00 Increased By ▲ 0.06 (0.16%)
AIRLINK 197.50 Increased By ▲ 3.59 (1.85%)
BOP 9.56 Increased By ▲ 0.24 (2.58%)
CNERGY 5.96 Increased By ▲ 0.12 (2.05%)
DCL 8.87 Increased By ▲ 0.19 (2.19%)
DFML 35.65 Decreased By ▼ -0.81 (-2.22%)
DGKC 97.50 Increased By ▲ 4.96 (5.36%)
FCCL 35.30 Increased By ▲ 1.33 (3.92%)
FFBL 89.00 Increased By ▲ 6.70 (8.14%)
FFL 13.21 Increased By ▲ 0.46 (3.61%)
HUBC 127.70 Increased By ▲ 7.09 (5.88%)
HUMNL 13.49 Decreased By ▼ -0.11 (-0.81%)
KEL 5.38 Increased By ▲ 0.16 (3.07%)
KOSM 7.00 Increased By ▲ 0.48 (7.36%)
MLCF 45.00 Increased By ▲ 2.89 (6.86%)
NBP 61.90 Increased By ▲ 2.09 (3.49%)
OGDC 215.50 Increased By ▲ 4.33 (2.05%)
PAEL 39.05 Increased By ▲ 1.47 (3.91%)
PIBTL 8.24 Increased By ▲ 0.17 (2.11%)
PPL 192.40 Increased By ▲ 2.08 (1.09%)
PRL 38.57 Increased By ▲ 0.40 (1.05%)
PTC 25.80 Increased By ▲ 2.35 (10.02%)
SEARL 105.98 Increased By ▲ 8.04 (8.21%)
TELE 8.28 Increased By ▲ 0.06 (0.73%)
TOMCL 35.25 Increased By ▲ 0.22 (0.63%)
TPLP 13.40 Decreased By ▼ -0.15 (-1.11%)
TREET 22.29 Decreased By ▼ -0.44 (-1.94%)
TRG 55.99 Increased By ▲ 3.12 (5.9%)
UNITY 33.00 Increased By ▲ 0.04 (0.12%)
WTL 1.62 Increased By ▲ 0.10 (6.58%)
AGL 38.00 Increased By ▲ 0.06 (0.16%)
AIRLINK 197.50 Increased By ▲ 3.59 (1.85%)
BOP 9.56 Increased By ▲ 0.24 (2.58%)
CNERGY 5.96 Increased By ▲ 0.12 (2.05%)
DCL 8.87 Increased By ▲ 0.19 (2.19%)
DFML 35.65 Decreased By ▼ -0.81 (-2.22%)
DGKC 97.50 Increased By ▲ 4.96 (5.36%)
FCCL 35.30 Increased By ▲ 1.33 (3.92%)
FFBL 89.00 Increased By ▲ 6.70 (8.14%)
FFL 13.21 Increased By ▲ 0.46 (3.61%)
HUBC 127.70 Increased By ▲ 7.09 (5.88%)
HUMNL 13.49 Decreased By ▼ -0.11 (-0.81%)
KEL 5.38 Increased By ▲ 0.16 (3.07%)
KOSM 7.00 Increased By ▲ 0.48 (7.36%)
MLCF 45.00 Increased By ▲ 2.89 (6.86%)
NBP 61.90 Increased By ▲ 2.09 (3.49%)
OGDC 215.50 Increased By ▲ 4.33 (2.05%)
PAEL 39.05 Increased By ▲ 1.47 (3.91%)
PIBTL 8.24 Increased By ▲ 0.17 (2.11%)
PPL 192.40 Increased By ▲ 2.08 (1.09%)
PRL 38.57 Increased By ▲ 0.40 (1.05%)
PTC 25.80 Increased By ▲ 2.35 (10.02%)
SEARL 105.98 Increased By ▲ 8.04 (8.21%)
TELE 8.28 Increased By ▲ 0.06 (0.73%)
TOMCL 35.25 Increased By ▲ 0.22 (0.63%)
TPLP 13.40 Decreased By ▼ -0.15 (-1.11%)
TREET 22.29 Decreased By ▼ -0.44 (-1.94%)
TRG 55.99 Increased By ▲ 3.12 (5.9%)
UNITY 33.00 Increased By ▲ 0.04 (0.12%)
WTL 1.62 Increased By ▲ 0.10 (6.58%)
BR100 11,739 Increased By 355.4 (3.12%)
BR30 36,418 Increased By 1206.5 (3.43%)
KSE100 109,513 Increased By 3238.2 (3.05%)
KSE30 34,513 Increased By 1160.1 (3.48%)

WASHINGTON: The single-shot Johnson & Johnson vaccine is highly effective in preventing severe Covid-19, including newer variants, according to documents released by the US Food and Drug Administration on Wednesday.

The news came as the regulator was set to convene an independent panel Friday that will likely vote to authorize the vaccine, making it the third available in the country hit hardest by the coronavirus pandemic.

In large clinical trials, the J&J vaccine’s efficacy against severe disease was 85.9 percent in the United States, 81.7 percent in South Africa, and 87.6 percent in Brazil.

Overall, among 39,321 participants across all regions, the efficacy against severe Covid-19 was 85.4 percent, but it fell to 66.1 percent when including moderate forms of the disease.

Crucially, analyses of different demographic groups revealed no marked differences across age, race, or people with underlying conditions.

The vaccine was generally well-tolerated, with no reports of severe allergic reactions (anaphylaxis), which have been seen in rare cases for the Pfizer and Moderna shots. Mild to moderate reactions, like injection-site pain, headache, fatigue and muscle pains were more likely to occur in younger participants than older. There were no reported deaths in the vaccine group, but five in the placebo group.

Comments

Comments are closed.